Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 228-067-3 | CAS number: 6107-56-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Toxicity to reproduction
Administrative data
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 002
- Report date:
- 2002
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Docosanoic acid
- EC Number:
- 204-010-8
- EC Name:
- Docosanoic acid
- Cas Number:
- 112-85-6
- Molecular formula:
- C22H44O2
- IUPAC Name:
- docosanoic acid
1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material:
60805X
- Purity:
85.9 wt%
- Impurities: C14-C20 Fatty acids:10.9%, C24fatty acids: 2.3%
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material:
avoid direct sunlight, store at room temperature
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- Crj: CD,SPF
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Japan, Hino, Tokyo
- Age at study initiation: 8 weeks
- Weight at study initiation: male: 312.1 - 363.7 g; female: 205.3 - 230.8 g
- Housing: metal wire floor cages
- Diet (ad libitum): CE-2, CLEA Japan
- Water (ad libitum): tap water
- Acclimation period: 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 24 ± 1
- Humidity (%): 50 - 65
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
prepared more frequently than once a week; aliquots were kept by each concentration refrigerated in airtight conditions
VEHICLE
- Justification for use and choice of vehicle (if other than water): due to insolubility in water
- Amount of vehicle (if gavage): 5 mL/kg bw
- Lot/batch no. (if required): V6H2050 - Details on mating procedure:
- - Impregnation procedure: cohoused
- M/F ratio per cage: 1/1
- Length of cohabitation: up to two weeks
- Proof of pregnancy: sperm in vaginal smear referred to as day 0 of pregnancy
- Further mating after two unsuccessful attempts: no
- After successful mating each pregnant female was caged (how): individually - Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- - males: 42 days
- females: from 14 days prior to mating to day 3 of lactation - Frequency of treatment:
- once daily
- Details on study schedule:
- - Age at mating of the mated animals in the study: 10 weeks
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- 13
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: based on preliminary result in a 14 day-repeated dose toxicity study, where no signs of toxicity were found
Examinations
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least once a day
DETAILED CLINICAL OBSERVATIONS: No
BODY WEIGHT: Yes
- Time schedule for examinations: males: days 1, 8, 15, 22, 29, 36, 42; pregnancy females: premating days 1, 8, 15; pregnancy days: 0, 7, 14, 20; lactation days: 0, 4; non pregnancy females: day 1, 8, 15, 22, 25
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
HAEMATOLOGY: Yes (males only)
- Time schedule for collection of blood: prior to autopsy
- Anaesthetic used for blood collection: Yes (identity): pentobarbital sodium
- Animals fasted: 18 - 24 hours before sacrifice
- How many animals: all surviving animals
- Parameters checked: red blood cell count (RBC), white blood cell count (WBC), haemoglobin content (Hb), mean corpuscular volume (MCV), ahematocrit (Ht), mean corpuscular haemoglobin content (MCH), mean corpuscular haemoglobin concentration (MCHC)
CLINICAL CHEMISTRY: Yes (males only)
- Animals fasted: 18 - 24 hours before sacrifice
- How many animals: all surviving animals
- Parameters checked: total protein, albumin, total cholesterol concentration, glucose, urea nitrogen, creatinine, alkaline phosphatase activity, GOT, GPT, γ-GTP, triglyceride concentration, inorganic phosphorus, total bilirubin, calcium, sodium, potassium, chlorine, A/G ratio
URINALYSIS: No - Oestrous cyclicity (parental animals):
- not examined
- Sperm parameters (parental animals):
- Parameters examined in all male parental generations:
testis weight, epididymis weight - Litter observations:
- STANDARDISATION OF LITTERS
- Performed on day 4 postpartum: no
PARAMETERS EXAMINED
The following parameters were examined in F1 offspring:
number and sex of pups, stillbirths, live births, postnatal mortality, presence of gross anomalies
GROSS EXAMINATION OF DEAD PUPS:
yes, for external and internal abnormalities; possible cause of death was determined for pups born or found dead. - Postmortem examinations (parental animals):
- SACRIFICE
Animals were fasted for 24 hours after the final administration.
- Male animals: all surviving animals
- Maternal animals: all surviving animals
Gross Pathology
Organ weights:
male: heart, liver, kidneys, thymus, testes, epididymides
female: heart, liver, kidneys, thymus, ovaries and uterus
Pathology and histopathology (control and 1000 mg/kg bw/day group):
male: heart, liver, spleen, kidney, adrenal, testis, epididymis, brain, thymus, bladder
Testes and epididymides were stored by fixing in buan solution, all other organs were fixed in 10% formalin. Paraffin sections were produced and histopathological examination was performed using hematoxylin-eosin staining.
female: brain,heart, liver, spleen, kidney, bladder, adrenal glands, thymus, uterus, ovaries
Ovaries were stored by fixing in buan solution, all other organs were fixed in 10% formalin. Sections were prepared and histopathological examination was performed.
Blood chemistry:
Males: blood was taken from a vein in the abdomen under sodium pentobarbital anesthesa.
The numbder of red blood cells (RBC), leukocytes (WBC), blood pigment (Hb), average red blood cell volume (MCV) were calculated. Platelet count was carried out using a Coulter Counter Model S-PLUS IV.
Average erythrocyte blood pigment (MCH), average erythrocyte blood pigment concentration (MCHC) were also examined. The leukocyte percentile ratio was calculated by staining the specimens with Geisma and Wright stain and examined under and optical microscope.
Following blood collection the presence of peptides was determined using the Biuret method. Albumin concentration (BCG), total cholesterol levels (COD), glucose concentration (Glucokinase G6PD), urea nitrogen concentration (UreaseGt.DH), creatinine concentration (Jaff), alkaline phosphatase activity (Paranitophenyl phosphate substrate method), GOT/GPT activity (SSCC) - (y-GTPActivityCGlutamyl-3-Carboxy-4-Nitroanirid substrate method), triglyceride concentration (GPO), inorganic phosphorus concentration (Molybdate Direct method), total bilirubin concentration (Bilirubin [Roche' KitSSeries), calcium concentration (OCPC), potassium concentration (ion electrode method), chlorine concentration (ion electrode method) were examined. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring not selected as parental animals were sacrificed at 4 days of age.
- These animals were subjected to postmortem examinations (macroscopic examination) as follows: external malformations, visceral malformations - Statistics:
- Yates test, Mann-Whitney U test, Fisher exact test, Bartlett test, Dunnett test, Scheffe test, Kruskal-Wallis test
- Reproductive indices:
- Copulation index = (number of copulated pairs / number of pairs mated) x 100
- Fertility index = (number of pregnant animals / number of copulated pairs) x 100
- Gestation index = (number of pregnant females with pups alive / number of pregnant females) x 100
- Implantation index = (number of implantation sites / number of corpora lutea) x 100- Offspring viability indices:
- Delivery index = (number of pups born / number of implantation sites) x 100
- Birth index = (number of pups alive on day 0 / number of implantation sites) x 100
- Live birth index = (number of pups alive on day 0 / number of pups born) x 100
- Sex ratio on day 0 = (number of males pups alive on day 0 / number of female pups alive on day 0) x 100
- Viability index = (number of pups alive on day 4 / number of pups alive on day 0) x 100
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Significant increase was observed in 100 mg/kg bw/day group, not considered to be related to treatment
- Food consumption and compound intake (if feeding study):
- effects observed, non-treatment-related
- Description (incidence and severity):
- significant decrease was observed in 100 mg/kg bw/day group during lactation, not considered to be related to treatment
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- significant decrease of mean corpuscular haemoglobin concentration in the 300 and 1000 mg/kg bw/day groups; fndings are not dose-dependent
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- significant decreased ALP level in all dose groups; significant decreased glucose level in the 1000 mg/kg bw/day group; signifant increase in chloride, decrease in calcium content and in total protein in the 300 mg/kg bw/day group; fndings are not dose-dependent and considered incidental
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- observations were considered incidential
- Histopathological findings: neoplastic:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- no effects observed
Details on results (P0)
- Males: no deaths or abnormalities in general condition were observed in any of the treated groups
- Females: no deaths were observed in any treated group
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
Males: significant increase (p<0.01) compared to control was observed in 100 mg/kg group between 8 - 15 days and between 15 - 29 days. However, since no change was observed in other groups, the effect was not considered to be related to the dosing of compound. No changes in food consumption related to the dosing of compound were observed.
- Females: no significant changes in body weight were noted and there were no changes related to the dosing of compound in body weight gain and food consumption. A significant decrease (p<0.01) compared to control was observed during lactation in 100 mg/kg dosing group. However, since no other changes in food consumption were noted in 300 mg/kg and 1000 mg/kg dosing groups, the effect was not considered to be related to the dosing of compound.
HAEMATOLOGY
- Males: a significant decrease (p<0.01) of mean corpuscular haemoglobin concentration (MCHC) compared to control was found in the 300 and 1000 mg/kg bw/day dose group, respectively (control: 34.7 ± 0.5%; 100 mg/kg bw/day: 34.4 ± 0.2%; 300 mg/kg bw/day: 33.9 ± 0.4%**; 1000 mg/kg bw/day: 33.9 ± 0.3%**; **p<0.01). No other differences were noted.
CLINICAL CHEMISTRY
- Males: a significant decreased ALP level (p<0.05) compared to control was found in all dosing groups (control: 237 ± 45 U/L; 100 mg/kg bw/day: 200 ± 35 U/L*; 300 mg/kg bw/day: 195 ± 35 U/L*; 1000 mg/kg bw/day: 197 ± 41 U/L*; *p<0.05). A significant decreased glucose level (p<0.05) compared to control was found in the high dose group (control: 152 ± 16 mg/dL; 1000 mg/kg bw/day: 135 ± 14 mg/dL*; *p<0.05). While a significant increase in chloride (p<0.05) was found in the 300 mg/kg bw/day group, a significant decrease in calcium content (p<0.01) and in total protein (p<0.05) was noted in this group. However, all the findings lack a dose-dependency and were regarded as incidental.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
There were no significant differences in number of corpora lutea, implantation rate, number of implantations and all other reproductive parameters in all treated groups compared to the control group.
ORGAN WEIGHTS (PARENTAL ANIMALS)
Males: in 100 mg/kg bw males, the actual weight ratio of liver weight (p <0.05) compared to control values were increased. No other significant differences were found in all groups. Thus, this finding lacks a dose-dependency and was regarded as incidental.
- Females: kidney weight was significantly reduced (p<0.05) in the 300 mg/kg bw group. No other weight changes were noted. Thus, this finding lacks a dose-dependency and was regarded as incidental.
GROSS PATHOLOGY (PARENTAL ANIMALS)
Males:
- Heart: myocardial degeneration was noted in one animal of the control group and the 1000 mg/kg bw group, respectively
- Liver: periportal fatty change of the liver was found in all animals of the control and the high dose group. Focal necrosis was noted in one animal of the high-dose group.
- Spleen: all animals of the control and the high-dose group showed brown pigment deposits of the spleen as well as extramedullary haematopeiosis
- Kidney: while fibrosis was only found in 1/13 animals of the control group, eosinophilic bodies and basophilic tubuli in the cortex were noted in animals of both control and high dose groups, respectively
- Adrenal gland: one animal of the high-dose group showed fibrosis
- Testis: atrophy of the seminiferous tubules was observed in two animals of the 1000 mg/kg dose group, with one animal affected on both sides and one side affected in the other animal. No other abnormalities were noted.
- Epididymis: abnormal sperm granuloma was found in one animal of the control group
- Brain: no abnormal findings noted
- Thymus: no abnormal findings noted
- Bladder: no abnormal findings noted
Females:
- Brain: one animal of the high-dose group showed abnormal mineral deposition in the thalamus
- Liver: focal necrosis and fibrosis was found in one animal of the control group, while one animal of the high-dose group showed only focal necrosis
- Spleen: brown pigmentation and extramedullary haematopeiosis was found in animals of the control and the high-dose group, but no varying degrees of frequency was observed
- Thymus: atrophy and bleeding was observed in animals of both groups, control and high-dose group, respectively
- Kidney: basophilic tubuli of the cotex and a dilatation of the renal pelvis was seen in the control and high-dose group
- Adrenal gland: cortical necrosis was observed in one animal of the control group
- Heart: no abnormal findings noted
- Bladder: no abnormal findings noted
Effect levels (P0)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse substance -related systemic effects and findings on fertility were noted
Target system / organ toxicity (P0)
- Key result
- Critical effects observed:
- no
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not examined
- Mortality / viability:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food efficiency:
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Histopathological findings:
- not examined
Developmental neurotoxicity (F1)
- Behaviour (functional findings):
- not examined
Developmental immunotoxicity (F1)
- Developmental immunotoxicity:
- not examined
Details on results (F1)
No change in number of birth, birth rate, infant live birth rate, infant survival and birth rates at day 4 was found in all dose groups compared to the values of the control group.
BODY WEIGHT (OFFSPRING)
No difference in bodyweight of pups of the dose groups and the control group was found.
GROSS PATHOLOGY (OFFSPRING)
No morphological abnormalities were found in all groups.
Effect levels (F1)
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- developmental
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no adverse substance-related findings were noted
Target system / organ toxicity (F1)
- Key result
- Critical effects observed:
- no
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- no
Any other information on results incl. tables
Table 1. Summary of development up of pups from dams treated orally with docosanoic acid in the combined repeat dose and reproductive/developmental toxicity screening test: Mean ± SD (N)
Dose group (mg/kg bw/day) |
0 |
100 |
300 |
1000 |
Number of pregnant females |
13 |
12 |
12 |
13 |
Number of pregnant females with live pups |
13 |
12 |
12 |
13 |
Gestation index |
100 |
100 |
100 |
100 |
Gestation length in days |
22.2±0.4 (13) |
22.4±0.5 (12) |
22.3±0.5 (12) |
22.2±0.4 (13) |
Number of corpora lutea |
16.6±1.6 (13) |
16.7±1.8 (12) |
16.8±2.3 (12) |
16.2±1.5 (13) |
Number of implantation sites |
16.1±1.5 (13) |
15.8±2.1 (12) |
16.0±1.5 (12) |
15.2±3.1 (13) |
Implantation index |
96.9±5.1 (13) |
94.8±7.1 (12) |
96.1±6.0 (12) |
93.1±15.2 (13) |
Day 0 of lactation |
|
|
|
|
Number of pups born |
15.2±1.6 (13) |
14.8±2.2 (12) |
15.2±1.5 (12) |
14.3±2.7 (13) |
Delivery index |
94.5±8.0 (13) |
93.5±3.9 (12) |
94.9±4.3 (12) |
94.9±6.2 (13) |
Number of live pups |
14.9±1.6 (13) |
14.3±2.2 (12) |
15.1±1.6 (12) |
14.1±2.7 (13) |
Birth index |
93.1±8.8 (13) |
90.7±8.7 (12) |
94.3±5.1 (12) |
93.5±7.2 (13) |
Live birth index |
98.5±2.8 (13) |
97.0±8.5 (12) |
99.4±2.2 (12) |
98.5±4.0 (13) |
Sex ration on day 0 |
50.0±11.3 (13) |
46.7±9.8 (12) |
54.8±12.3 (12) |
48.9±13.4(13) |
Day 4 of lactation |
|
|
|
|
Number of live pups |
14.7±1.4 (13) |
13.0±4.7 (12) |
15.1±1.6 (12) |
14.1±2.7 (13) |
Viability index |
98.6±2.7 (13) |
89.4±28.8 (12) |
100.0±0.0 (12) |
100.0±0.0 (13) |
Sex ration on day 4 |
49.8±11.5 (13) |
46.3±10.3 (11) |
54.8±12.3 (12) |
48.9±13.4(13) |
Applicant's summary and conclusion
- Conclusions:
- No deaths were observed in any group, and no changes in general conditions, weight and feeding were observed. After 42 doses there were some decreases noted in the average red blood pigment concentration in males in the 300 mg/kg group, glucose levels decreased significantly in the 1000 mg/kg group. However, since both changes were mild and there were no associated changes in other test items, including pathological examinations, these were considered to be incidental changes and of no toxicological significance. In histopathological examination, two of the animals in the1000 mg/kg group showed very mild microtubule atrophy. As these were very mild and localized, and there were no other changes, these were note considered to be of concern.
These results conclude that under these test conditions, the NOAEL for repeated administration of docosanic acid in regard to reproduction and fertility is 1000 mg/kg/day. - Executive summary:
Docosanic acid is a mixture ofhigh-grade saturated fatty acids contained intheconstituent fatty acids of carasi oil and rapeseedoil. Industrially, it is distilled and purified after the rapeseed oil is hydrolyzed mainly as a raw material, but it has recently come to be used as a raw material for cosmetics. There is very little information in regard to the toxicity and hazards associated with docosanic acid. A study was conducted to evaluate docosanoic acid. 0 (solvent control), 100, 300 and 1000 mg/kg of docosanoic acid was administered to
Sprague-Dawley (Crj:CD)rats, male andfemale, (13 animals / group), started 2weeksbefore matingand 42 days in total for males. For females administration started 2 weeks before mating and continued until 3 days after the start of lactation. Parent animals and infants were examined for effects of repeated administration on the toxicity, fertility, as well as development of the next generation infants.
No abnormalities or death were observed in any docosanic acid administration group in males. In addition, there was no observed changes in weight and feeding . Autopsy results from histopathological, hematology, hematology and hemobiochemistry tests showed no indications of toxicity or abnormal values attributed to the administration of docosanoic acid.
In females, there were no deaths in any of the docosanic acid administration groups. In addition, changes in general condition, weight, and feeding amount were not observed. In the autopsy and histopathological examination four days after delivery, there were no findings suggesting of effects as a result of docosanic acid administration.
Furthermore, docosanic acid administered in doses up to 1000 mg/kg did not affect mating rate and conception rate. In addition, there were no changes to suggest effects of docosanic acid administration on pregnancy, birth rate, delivery, and baby-care bythe mother.
There were no changes in the sex ratio, weight, and survival rate of birth children attributed to the effects of docosanic acid administration. In addition, morphological abnormalities in birth children were not observed in any docosanic acid administration group. These results conclude that under these test conditions, the NOAEL for repeated administration of docosanic acid in regard to reproduction and fertility is 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.